SPRY R&D to Revenue
Ars Pharmaceuticals Inc · R&D to Revenue
SPRY R&D to Revenue
Latest reported13.96%period ending
SPRY Quarterly R&D/Revenue (0.00% → 13.96%)
Latest values, visible window
High-resolution chart · PNG
SPRY r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 13.958% | |
| 19.1173% | |
| 12.2583% | |
| 8.4644% | |
| 25.6728% | |
| 37.025% | |
| 3.4961% | |
| 213.8781% | |
| 1,379.2% | |
| 0% | |
| 0% | |
| 0% | |
| 73,080% | |
| 32,760% | |
| 0% | |
| 2,059.7884% | |
| 937.5% | |
| 817.9487% | |
| 519.0981% | |
| 970.0758% | |
| 266.0275% | |
| 266.0275% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |